The GSK oncology products it has sold on to Novartis were ... particularly if GSK is not looking to reinvest in oncology. However a major outlay looks unlikely, at least in connection to the ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

Three years after the discovery of the human immunodeficiency virus (HIV) in 1984, GlaxoSmithKline's (GSK ... it was found that major and prolonged reductions in viral burden could be achieved ...

India's GlaxoSmithKline Pharma reports higher profit ... two deals with Pfizer worth a combined $897 million to manufacture products for the U.S. pharmaceutical giant. May 19, 2023 Abbott's ...